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Objective : Silent corticotroph adenomas (SCA) are endocrine-inactive pituitary adenomas with positive immunohistochemistry 
staining for adrenocorticotropic hormone (ACTH). We investigated whether SCA-associated clinical profiles were more aggressive 
than hormonally negative adenomas (HNA).
Methods : Among 627 patients with pathologically proven endocrine-inactive pituitary adenomas between 2004 and 2013, 
positive immunohistochemistry revealed 55 SCAs and 411 HNAs. Surgical outcomes and radiological and endocrinological 
characteristics were compared.
Results : Strong female predominance was observed in the SCA group (p<0.001). Cavernous sinus invasion was identified in 22 
(40%) SCA patients and 72 (17.6%) HNA patients (p<0.001). There were no differences in ACTH or cortisol levels between the two 
groups. The incidence of preoperative hypopituitarism and postoperative hormonal outcome did not differ between two groups. 
Total resection was achieved in 35 patients (63.7%) with SCA and 332 patients (80.8%) with HNA (p=0.007). When tumors were 
completely removed, recurrence rates were not statistically different between two groups (p=0.60). When complete resection was 
not achieved, tumors regrew from these remnants in seven patients (35.0%) with SCA and 12 patients (15.2%) with HNA (p=0.05).
Conclusion : Total surgical resection for SCA is often challenging as these tumors frequently invade a cavernous sinus. Early 
remnant tumor intervention is justified, because untreated residual pituitary tumors regrow when patients were followed up for a 
long time. Prophylactic radiotherapy is not warranted for completely resected SCAs as tumor recurrence is uncommon.
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INTRODUCTION
Pituitary adenomas are the third most common brain tu-
mor, requiring different treatment strategies based on their 
hormonal activities. When a tumor does not produce any hor-
mones, patients remain asymptomatic until the tumor be-
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comes a macroadenoma, presenting a mass effect over an op-
tic apparatus, the hypothalamus, and adjacent blood vessels. 
Although clinically non-functioning pituitary adenomas 
(NFPAs) comprise about 25% of all pituitary adenomas, they 
are quite heterogeneous in nature, as they include null cell ad-
enomas, various types of silent adenomas and even gonado-
troph adenomas. 
Silent corticotroph adenomas (SCAs) are a subtype of NF-
PAs which exhibit positive immunoreactivity for adrenocorti-
cotropic hormone (ACTH) without the clinical or biochemi-
cal features of hypercortisolism. Hormonally negative 
adenomas (HNAs) refer to null cell adenomas, which are neg-
ative for any immunohistochemical staining. SCAs comprise 
2.9–5.7% of pituitary adenomas in surgical series2,5). Previous 
reports suggest that the high rate of SCA recurrence and re-
growth from residual tumor remnants may necessitate adju-
vant treatments, such as radiation therapy13,15).
Based on our experience with 55 SCA cases, we clinically 
characterized SCAs and evaluated the surgical outcome of 
SCAs compared with HNAs.
MATERIALS AND METHODS
Patients
A total of 627 patients with NFPAs treated surgically at our 
institution from 2004 until 2013, were recruited from our pi-
tuitary tumor database and analyzed retrospectively. Reports 
on immunohistochemical staining were available for 620 pa-
tients. Gonadotroph adenomas and other silent adenomas 
were excluded from this study based on immunohistochemi-
cal staining for pituitary hormones. Fifty-five SCA cases and 
411 HNA cases were included and compared. The diagnoses 
of SCAs were based on the lack of clinical symptoms of hyper-
cortisolism, the lack of laboratory data consistent with hyper-
cortisolism, and the finding of positive ACTH immunoreac-
tivity. This paper was reviewed and approved by Severance 
Hospital Institutional Review Board.
Radiological evaluation
All patients underwent preoperative dynamic magnetic res-
onance imaging (MRI) of the sellar region, using a 1.5-Tesla 
system (Signa; General Electric, Minneapolis, MN, USA) or a 
3.0-Tesla system (Achieva; Philips, Best, The Netherlands). 
The MRI evaluation included spin-echo T1-weighted (TR 500 
ms/TE 20 ms) imaging, T2-weighted (TR 3500 ms/TE 100 ms) 
imaging, and dynamic contrast-enhanced (TR 400 ms/TE 10 
ms) imaging after intravenous administration of gadolinium-
diethylenetriamine pentaacetic acid (0.1 mL/kg of body 
weight) with a temporal resolution of 25 seconds. Immediate 
postoperative 3-Tesla diagnostic MRI was performed within 
48 hours after surgery; the radicality of tumor removal was 
determined. Follow-up MRI was performed 1 year after sur-
gery and every other year thereafter.
All adenomas were classified according to a modified Hardy 
radiological classification scheme8,9). Type I was confined en-
tirely within the sellae and had a size <1 cm. Type II extended 
into the suprasellar space, up to <1 cm above the line of the 
diaphragm. Type III extended into the suprasellar area, up to 
>1 cm above the line of the diaphragm, or extended into the 
sphenoid sinus. Type IV was defined as a tumor that invaded 
the cavernous sinus. In addition, Hardy type IV lesions were 
further classified according to the Knosp classification to 
demonstrate the degree of cavernous sinus invasions.
Extent of resection, recurrence of the tumor, and regrowth 
of the remnant were determined based on postoperative MRI 
findings, which were judged by a neurosurgeon and a radiolo-
gist. The size of the tumor was defined as the longest diameter 
of the tumor, as seen in the coronal MRI view.
Endocrinological evaluation
Basal serum levels of pituitary hormones (including prolactin, 
luteinizing hormone [LH], follicle-stimulating hormone [FSH], 
thyroid-stimulating hormone [TSH], growth hormone [GH], and 
ACTH) along with cortisol, T3, free T4, insulin-like growth fac-
tor-1, and estradiol or testosterone were checked at 8:00 am before 
surgery and 1 week, and 1, 3, 6, and 12 months after surgery. Pre-
operative serum cortisol levels and 24-hour urinary free cortisol 
levels were compared between patients having SCA and those 
with HNA to evaluate the baseline levels and subgroup differenc-
es. Preoperative serum cortisol and ACTH levels were compared 
to postoperative hormone levels in the SCA group to determine if 
surgery affected hormonal regulation. The HNA group was ana-
lyzed in the same manner to determine if there was a procedural 
effect on hormonal regulation.
Endocrinological assessment with a combined pituitary func-
tion test (CPFT) was fully described in our previous report10). 
TSH levels were measured by chemiluminescent microparticle 
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immunoassay using ARCHITECT TSH Reagent kit (Abbott 
Laboratories, Longford, Ireland). LH, FSH, prolactin, and cortisol 
levels were all measured by sandwich ELISA using Access Reagent 
Pack (Backman Coulter Inc., Brea, CA, USA). GH levels were 
measured by chemiluminescence immunoassay using LIAISON 
hGH Reagent (DiaSorin, Saluggia, Italy), and ACTH levels were 
measured by electrochemiluminescence immunoassay (Roche 
Diagnostics, Mannheim, Germany). The results for both preop-
erative and postoperative CPFT were available for 303 patients (34 
patients with SCA and 269 patients with HNA). The CPFT was 
interpreted as described below and the results were confirmed by 
two endocrinologists. After intravenous injection of 0.1 U/kg regular 
insulin, thyrotropin-releasing hormone (500 mcg), and LH-re-
leasing hormone (100 mcg), patients were evaluated serially for 2 
hours for their responses of serum GH, cortisol, ACTH, LH, FSH, 
TSH, and prolactin (PRL). The criteria for normal responses were 
as follows : peak GH level increased by >3 ng/mL, peak cortisol in-
creased by >180 ng/mL or >70 ng/mL compared with basal level, 
basal PRL level was 2–15 ng/mL, and peak PRL level increased 
>2-fold of basal PRL level, peak TSH level increased greater than 
5 IU/mL compared with basal level and free T4 was in the nor-
mal range, peak FSH increased >2 mIU/mL compared with 
basal level, and peak LH increased greater than 10 mIU/mL com-
pared with basal level. Elevated levels of basal gonadotropins in 
postmenopausal patients and no menstrual disorders in pre-
menopausal patients were regarded as normal. Changes in pitu-
itary function before and after transsphenoidal approach (TSA) 
were classified into four categories : 1) normal to normal (no pitu-
itary hormone deficiency before and after TSA); 2) improved hy-
popituitarism (hypopituitarism improved, including complete 
recovery); 3) persistent hypopituitarism (the degree of pituitary 
hormone deficiency did not change after TSA); and 4) worsened 
hypopituitarism (the number and/or degree of pituitary hormone 
deficiency worsened after TSA). The last of these categories in-
cluded the new development of postoperative hypopituitarism 
and the aggravation of preoperatively existing hypopituitarism. 
CPFT was performed to evaluate anterior pituitary function be-
fore surgery, 6–12 months after surgery, and every 2 years there-
after.
Surgical procedure
The surgical procedure was performed in the conventional 
microscopic TSA by two neurosurgeons (S.H.K. and E.H.K.). 
After dural opening, we first localized the normal pituitary 
gland and checked for tumor consistency and the presence of 
a pseudocapsule. During tumor removal, we made every ef-
fort to preserve a normal remaining pituitary gland whereas 
the pseudocapsule was always removed as radically as possible. 
With any faint suspicion of dural invasion, all exposed dura 
mater was removed as much as possible. In five cases with gi-
ant pituitary macroadenomas, the transcranial approach was 
performed for better tumor visualization and removal as the 
initial treatment. For the tumors invading a cavernous sinus, 
the tumor was removed as much as possible through a win-
dow on the medial wall of the cavernous sinus. However, for 
endocrine-inactive tumors, the direct approach to the lateral 
compartment of a cavernous sinus was not performed. When 
cerebrospinal f luid (CSF) leakage was noted after tumor re-
moval, it was sealed by various direct closure techniques to 
close the leaking point. Postoperative lumbar drainage of CSF 
was performed in many of our early cases; however, it has not 
been used since 2005. Most of the remnant tumors were only 
observed until regrowth was evident on serial follow-up 
MRIs. Secondary treatment options included re-operation, 
gamma knife radiosurgery and radiotherapy.
Statistical analysis
For categorical analysis, a chi square test and Fisher’s exact 
test were used. Survival analysis was performed by Kaplan-
Meier method in order to demonstrate progression-free sur-
vival after resection for each subgroup and to compare the 
outcome related to the suspected risk factors. All analyses 
were conducted using IBM SPSS Statistics (version 20.0; IBM, 




The clinical characteristics of our 466 patients are summa-
rized in Table 1. The median follow-up duration was not sta-
tistically different between the SCA and HNA groups (SCA, 
20.0 months; HNA, 31.0 months). The mean age at diagnosis 
was 49.7 years in 55 patients with SCA and 49.8 years in 411 
patients with HNA, which was not statistically different 
(p=0.96). The SCA group included 11 males and 44 females, 
whereas the HNA group included 196 males and 215 females. 
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The male-to-female ratio (11 : 44) in the SCA group revealed 
female dominance in this subtype compared with the HNA 
group (p<0.001).
The mean tumor size during preoperative MRI was 28.6±11.8 
mm and 27.0±8.9 mm for SCAs and HNAs, respectively; there 
was no intergroup difference (p=0.46). To evaluate cavernous si-
nus invasion of the tumor, we primarily depended on preopera-
tive MRI images, but surgical findings played decisive roles when 
cavernous sinus invasions were noted during the surgeries even if 
the preoperative MRI could not confirm the invasion. In the SCA 
group, cavernous sinus invasion was detected on preoperative 
MRI in 22 patients (40%) among whom one patient was Knosp 
grade II, four were Knosp grade III, and 17 were Knosp grade IV, 
whereas only 72 patients (17.5%) with HNA displayed cavernous 
invasion, among whom one patient was Knosp grade I, 10 were 
Knosp grade II, 32 were Knosp grade III and 29 were Knosp grade 
IV. SCA group revealed a higher rate of a cavernous sinus inva-
sion (p<0.001).
Endocrinological outcome
Preoperative and postoperative hormone levels in the SCA 
and HNA groups are summarized in Table 2. No statistically 
significant differences were found between the SCA and HNA 
groups, either preoperatively or postoperatively. Serum ACTH 
and cortisol levels decreased in both groups whereas the 24-
hour urinary free cortisol levels rather increased postopera-
tively.
Preoperatively, the incidence of hypopituitarism was not 
different identified between two groups (64.7% in SCA group 
vs. 74.3% in HNA group, p=0.16). Comparisons between pre-
operative and postoperative CPFT were available in 303 pa-
tients (Table 3). Overall, normal pituitary function was pre-
served in 69 (22.8%), improved in 146 (48.2%), persistent in 48 
(15.8%), and aggravated in 40 patients (13.2%). No statistically 
significant differences were found between the SCA and HNA 
groups (p=0.584).
Table 1. Patient demographics
SCA HNA p-value




Mean age (years) 49.7 49.8 0.96
Duration of follow up (months) 20.0 (3–122) 31.0 (3–122) 0.881
Size of tumor (mm) 28.6±11.8 27.0±8.9 0.46
Cavernous sinus invasion 22 (40) 72 (17.5) <0.001*
Values are presented as mean±standard deviation, number (%), or number (range). *Statistically significant. SCA : silent corticotroph adenoma, HNA : 
hormonally negative adenoma 
Table 2. Preoperative and postoperative hormone level
SCA HNA p-value
ACTH (pg/mL)
Preoperative 48.8 36.4 0.09
Postoperative 24.2 23.1 0.75
Serum cortisol (mcg/dL)
Preoperative 12.6 11.4 0.18
Postoperative 9.9 10.5 0.51
24-hours urinary free cortisol (mcg/dL)
Preoperative 184.2 183.3 0.98
Postoperative 292.5 292.6 0.99
SCA : silent corticotroph adenoma, HNA : hormonally negative adenoma
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Surgical outcome
Surgical outcome is summarized in Table 4. The transcra-
nial approach was performed as initial treatment in two SCA 
cases and three HNA cases. Total resection was achieved in 
63.7% of SCA patients and in 80.8% of HNA patients 
(p=0.007). When cavernous sinus was invaded, total resection 
was possible in 27.3% of SCA patients and in 23.6% of HNA 
patients. Postoperative CSF rhinorrhea developed in two SCA 
cases and four HNA cases (p=0.15).
Results regarding tumor recurrence and tumor remnant re-
growth are shown in Table 5. In the HNA group, follow-up 
MRIs detected recurrent tumors in five patients (1.2%) whose 
tumors were previously completely resected; no patients with 
SCA experienced tumor recurrence (p=0.41). Serial follow-up 
MRIs demonstrated regrowth in seven of 20 patients (35.0%) 
with remnant SCA and in 12 of 79 patients (15.2%) with rem-
nant HNA (p=0.05). Time to progression from the initial op-
eration between the two subgroups did not show statistically 
significant difference, with 49 months in the SCA group and 
46 months in the HNA group (p=0.56). All patients with re-
grown remnant tumors required adjuvant treatments, includ-
ing re-operation, gamma knife surgery, and conventional ra-
diotherapy. Actuarial progression-free survival at 12, 24, and 
48 months after operation was 97.4%, 90.2%, and 84.9% in 
the SCA group, and 99.1%, 98.5%, and 96.2% in the HNA 
group, respectively (p=0.009) (Fig. 1).  Although SCAs showed 
more invasive feature with more frequent recurrence, recur-
rence was not common once total removal as achieved (Fig. 
Table 3. Postoperative hormonal outcome
Postoperative hormonal outcome SCA HNA p-value
Preserved normal pituitary function (n=69, 22.8%) 9 (26.5) 60 (22.3) 0.66
Improved hypopituitarism (n=146, 48.2%) 14 (41.2) 132 (49.1) 0.47
Persistent hypopituitarism (n=48, 15.8%) 6 (17.6) 42 (15.6) 0.80
Aggravation of hypopituitarism (n=40, 13.2%) 5 (14.7) 35 (13.0) 0.78
Total (n=303)* 34 269 0.854
Values are presented as number (%). *Total number of patients in whom comparison between preoperative and postoperative combined pituitary 
function test was available. SCA : silent corticotroph adenoma, HNA : hormonally negative adenoma
Table 4. Surgical outcome
SCA HNA p-value
Surgical approach 0.11
Transsphenoidal approach 53 (96.4) 408 (99.2)
Transcranial approach 2 (3.6) 3 (0.7)
Total resection 35 (63.7) 332 (80.8) 0.007*
Postoperative CSF rhinorrhea 2 (4) 4 (1) 0.15
Values are presented as number (%). *Statistically significant. SCA : silent corticotroph adenoma, HNA : hormonally negative adenoma, CSF : 
cerebrospinal fluid 
Table 5. Recurrence and regrowth
SCA HNA p-value
Remnant growing* 7 (35.0) 12 (15.2) 0.05
Recurrence (cases) 0 5 (1.2) 0.41
Time to progress (months) 49 (11–89) 46 (11–100) 0.56






Values are presented as number (%) or number (range) unless otherwise indicated. *This indicates the number of patients with adenoma regrown 
from residual tumor after subtotal resection. SCA : silent corticotroph adenoma, HNA : hormonally negative adenoma
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2A). In 55 patients with SCA, the progression-free survival 
curve showed a high probability of regrowth when total resec-
tion was not achieved (Fig. 2B).
Case illustration
A 51-year old male patient presented with a symptom of vi-
sual disturbance. He was a hepatitis B-virus carrier without 
any other significant medical history. Visual field evaluation 
revealed that the patient has a typical bitemporal hemianop-
sia. Brain MRI showed a pituitary macroadenoma with signif-
icant optic nerve compression and right cavernous sinus inva-
sion (Fig. 3A). Tumor was removal with TSA leaving a small 
remnant in right cavernous sinus (Fig. 3B). Visual field defect 
improved after surgical treatment. A year after the surgery, 
MRI revealed increase in the size of residual tumor in the 
right cavernous sinus (Fig. 3C), which was then irradiated by 
Gamma Knife radiosurgery (GKS) with 14 Gy of margin dose. 
The tumor was under control until 7-year post-GKS MRI re-
vealed recurrent tumor in the intrasellar and suprasellar space 
as well as inside right cavernous sinus (Fig. 3D). The recurrent 
tumor was removed by two times of surgery; extended TSA 
for intrasellar and right cavernous sinus exploration and su-
Fig. 2. Kaplan-Meyer curve of progression-free survival in 55 patients with SCA. A : The extent of resection was a strong prognostic factor) as no patient 
experienced recurrence when their tumors were completely removed. B : When tumors were not completely removed, SCAs showed worse prognosis 
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Fig. 1. Progression-free survival of nonfunctioning pituitary adenomas. 
The SCA group has a reduced survival outcome when compared with the 
HNA group (p=0.009). The SCA group’s actuarial survival rate at 12, 24, and 
48 postoperative months was 97.4%, 90.2%, and 84.9%, respectively. HNA : 
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praorbital keyhole transcranial approach for the removal of 
suprasellar tumor. After radical removal of the recurrent tu-
mor, MRI revealed no visible tumor (Fig. 3E). Histopathologi-
cal findings were consistent with a pituitary adenoma on H&E 
stain and immunohistochemistry for ACTH was positive (Fig. 
3G-I). Despite aggressive surgical resection, recurrent tumor 
was found inside right cavernous sinus and suprasellar space 
on the MRI taken 3 years after second surgery (Fig. 3F), which 
necessitated 2nd GKS.
Fig. 3. Illustrative case with a silent corticotroph adenoma. A 51-year old male patient was diagnosed as a pituitary macroadenoma with significant 
optic nerve compression and right cavernous sinus invasion (A). Tumor was removal with transsphenoidal approach leaving a small remnant in right 
cavernous sinus (black arrow, B). A year after the surgery, MRI revealed increase in the size of residual tumor in the right cavernous sinus (C). After GKS, 
the tumor was under control until 7-year post-GKS MRI revealed recurrent tumor in the intrasellar and suprasellar space as well as inside right cavernous 
sinus (white arrowheads, D). After radical removal of the recurrent tumor, MRI revealed no visible tumor (E), however, 3 years later, recurrent tumor was 
found again inside right cavernous sinus and suprasellar space (white arrow, F). Histopathological examination demonstrated a pituitary adenoma (G; 
H&E, ×400) with positive immunohistochemistry for adrenocorticotropic hormone (H; ACTH, ×200). Ki-67 labeling index was only 1–2% (I; Ki-67, ×200). 










  Surgery for Silent Corticotroph Adenoma | Kim J, et al.
121J Korean Neurosurg Soc 62 (1) : 114-122
DISCUSSION
Silent pituitary macroadenomas and their char-
acteristics
The female dominance in the SCA group is a very interest-
ing finding in our series, which is also very distinct character-
istic of Cushing’s disease. This finding has not been previously 
reported in a major SCA series. When we consider that both 
SCA and Cushing’s disease originate from corticotroph cells 
and share similar molecular pathogenesis involving proopi-
omelanocortin and prohormone convertase 1/37), female 
dominance in SCA is not unexpected.
There have been many reports suggesting that SCAs are 
more likely to invade adjacent anatomical structures, such as a 
cavernous sinus1,2,6,7,12,13). In our study, the incidence of cavern-
ous sinus was 40.0% in patients with SCA, which is much 
higher than the incidence seen in patients with HNA (17.5%). 
However, there was no difference in patient age or tumor size. 
Endocrinological aspect
ACTH and cortisol levels were slightly higher in the SCA 
group than in the HNA group; however, this difference was 
not statistically significant. We excluded the possibility that 
the SCA group included cases of ACTH-secreting pituitary 
adenoma (Cushing’s disease) based on preoperative measure-
ment of 24-hour urinary free cortisol. ACTH and cortisol lev-
els did not differ after surgery. Both serum ACTH levels and 
serum cortisol hormone levels were somewhat decreased after 
surgery, which may be the result of surgical traumatization on 
the normal pituitary gland. Urine cortisol levels showed no 
statistically significant intergroup difference between each 
groups’ preoperative and postoperative status. The 24-hour 
urinary free cortisol levels were rather increased after surgery 
in both SCA and HNA groups. As the level of 24-hour urinary 
free cortisol largely depends on BMI and co-morbidities such 
as diabetes, further well controlled in-depth study might be 
necessary to clarify this confusing result.
It has been reported that hypopituitarism more commonly 
develops in patients with SCA6). However, our result did not 
indicate a higher incidence of hypopituitarism in the SCA 
group, but rather a slightly higher incidence in the HNA 
group. After surgery, hormonal outcomes were judged by 
comparing preoperative and postoperative CPFT, which re-
vealed no differences between the SCA and HNA groups.
Recurrence and regrowth
In our series, the chance of total resection was much lower 
in the SCA group than in the HNA group, which is consistent 
with the more frequent preoperative cavernous sinus invasion 
by SCAs. Although SCAs have a higher recurrence risk1,2,6,7,12,13), 
the recurrence rate in our series was not significantly higher 
than that of other NFPAs when tumors were completely re-
moved (p=0.60). Several studies report higher recurrence rates 
after surgical resection13,14) but their results lack a comparative 
group with other pituitary tumor resections. Bradley et al.3) 
found that SCA recurrence rate was not higher compared with 
NFPA, but they did not distinguish between regrowth and re-
currence. In this study, remnant regrowth was distinguished 
from true recurrence after total resection; the regrowth rate 
was 35%, which does not differ greatly from other reports3,4). 
The low recurrence rate may be related to our surgical strategy 
to remove all entities related to the pituitary tumor, including 
the tumor capsule9,10). Especially, when pituitary pseudocap-
sule was think enough to be used as a surgically available dis-
section plane, en bloc tumor resection was always tried. And, 
even when tumors were remove in piecemeal fashion, pseudo-
capsule was removed as radical as possible.
It is very important to be aware that SCAs are not uncom-
mon, as they comprise 8.8% (55 of 620 cases) of all endocrine-
inactive pituitary adenomas. Because detailed hormonal diag-
nosis based on immunohistochemistry is only available after 
surgery, radical tumor resection should be attempted whenev-
er possible. Traditionally, surgical resection has frequently 
been followed by radiation in order to lower the recurrence 
rate. However, this study suggests that prophylactic radiation 
is not necessary when SCAs are completely removed. This is 
also supported by other studies, which suggest that the role of 
irradiation needs to be reassessed for its low recurrence rate, 
particularly when tumors are resected completely1,11).
It is noteworthy that the SCA regrowth rate from remnant 
tumors was higher than that of HNA in this study. When 
remnants persisted after surgery, the overall regrowth rate was 
35.0% for SCAs, while its 8-year progression-free survival was 
only 31%. Therefore, rather than a “wait and see” approach, 
more meticulous follow up is mandatory and early interven-
tion with radiosurgery or radiotherapy can be recommended.
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CONCLUSION
Total surgical resection of SCAs is often impossible as these 
tumors frequently invade a cavernous sinus. As untreated re-
sidual SCAs have a higher chance to regrow, more meticulous 
follow up is mandatory and early intervention on remnant tu-
mors is recommended. Complete tumor removal is critical in 
the treatment of SCAs as it dramatically decrease the risk of 
recurrence, and thus, radical surgical resection should be at-
tempted whenever possible, even for endocrine-inactive pitu-
itary adenomas. Prophylactic radiotherapy is not warranted 
for SCAs that have been completely removed, as tumor recur-
rence is rare.
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